A 79175

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571192

CAS#: 141579-87-5

Description: A 79175 is a 5-lipoxygenase inhibitor that increases bone formation. It may also have potential as a cancer chemoprotective agent.

Chemical Structure

A 79175
CAS# 141579-87-5

Theoretical Analysis

MedKoo Cat#: 571192
Name: A 79175
CAS#: 141579-87-5
Chemical Formula: C15H13FN2O4
Exact Mass: 304.0859
Molecular Weight: 304.28
Elemental Analysis: C, 59.21; H, 4.31; F, 6.24; N, 9.21; O, 21.03

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: A 79175; A-79175; A79175

IUPAC/Chemical Name: Urea, N-(3-(5-(4-fluorophenoxy)-2-furanyl)-1-methyl-2-propynyl)-N-hydroxy-, (R)-


InChi Code: InChI=1S/C15H13FN2O4/c1-10(18(20)15(17)19)2-5-12-8-9-14(21-12)22-13-6-3-11(16)4-7-13/h3-4,6-10,20H,1H3,(H2,17,19)/t10-/m1/s1

SMILES Code: O=C(N)N([C@H](C)C#CC1=CC=C(OC2=CC=C(F)C=C2)O1)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 304.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Cottrell JA, Keshav V, Mitchell A, O'Connor JP. Local inhibition of 5-lipoxygenase enhances bone formation in a rat model. Bone Joint Res. 2013 Feb 1;2(2):41-50. doi: 10.1302/2046-3758.22.2000066. Print 2013 Feb. PubMed PMID: 23610701; PubMed Central PMCID: PMC3626215.

2: Carter GW, Bell RL, Marsh K, Lanni C, Awni WM, Bouska J, Stewart AO, Hansen R, Dubé L, Brooks DW. Stereoselective metabolism of the 5-lipoxygenase inhibitor A-78773. Ann N Y Acad Sci. 1994 Nov 15;744:262-73. PubMed PMID: 7825849.

3: Bell RL, Bouska JB, Malo PE, Lanni C, Harris RR, Otis ER, Stewart AO, Brooks DW, Carter GW. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. J Pharmacol Exp Ther. 1995 Feb;272(2):724-31. PubMed PMID: 7853186.

4: Rioux N, Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis. 1998 Aug;19(8):1393-400. PubMed PMID: 9744535.

5: Bell RL, Lanni C, Malo PE, Brooks DW, Stewart AO, Hansen R, Rubin P, Carter GW. Preclinical and clinical activity of zileuton and A-78773. Ann N Y Acad Sci. 1993 Nov 30;696:205-15. PubMed PMID: 8109828.

6: Bell RL, Brooks DW, Young PR, Lanni C, Stewart AO, Bouska J, Malo PE, Carter GW. A-78773: a selective, potent 5-lipoxygenase inhibitor. J Lipid Mediat. 1993 Mar-Apr;6(1-3):259-64. PubMed PMID: 8395248.

7: Rao TS, Currie JL, Shaffer AF, Isakson PC. Evaluation of 5-lipoxygenase inhibitors, zileuton, A-78773 and ICI-D-2138 in an ionophore (A-23187)-induced pleural inflammation model in the rat. Life Sci. 1993;53(9):PL147-52. PubMed PMID: 8394967.

8: Hulkower KI, Pollock JS, Walsh RE, Huang R, Otis ER, Brooks CD, Bell RL. Leukotrienes do not regulate nitric oxide production in RAW 264.7 macrophages. Prostaglandins Leukot Essent Fatty Acids. 1996 Sep;55(3):145-9. PubMed PMID: 8931110.

9: Nair DG, Funk CD. A cell-based assay for screening lipoxygenase inhibitors. Prostaglandins Other Lipid Mediat. 2009 Dec;90(3-4):98-104. doi: 10.1016/j.prostaglandins.2009.09.006. Epub 2009 Oct 3. PubMed PMID: 19804839.

10: Anderson GD, Keys KL, De Ciechi PA, Masferrer JL. Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. Inflamm Res. 2009 Feb;58(2):109-17. doi: 10.1007/s00011-009-8149-3. PubMed PMID: 19184362.

11: Smith WG, Shaffer AF, Currie JL, Thompson JM, Kim S, Rao T, Isakson PC. Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays. J Pharmacol Exp Ther. 1995 Dec;275(3):1332-8. PubMed PMID: 8531100.

12: Albert DH, Malo PE, Tapang P, Shaughnessy TK, Morgan DW, Wegner CD, Curtin ML, Sheppard GS, Xu L, Davidsen SK, Summers JB, Carter GW. The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J Pharmacol Exp Ther. 1998 Jan;284(1):83-8. PubMed PMID: 9435164.

13: Negro JM, Miralles JC, Ortiz JL, Funes E, García A. Biosynthesis inhibitors for leukotrienes in bronchial asthma. Allergol Immunopathol (Madr). 1997 Jul-Aug;25(4):209-16. Review. PubMed PMID: 9269512.

14: Harris RR, Wilcox D, Bell RL, Carter GW. The role of tissue mast cells in polyacrylamide gel-induced inflammation in mice. Inflamm Res. 1998 Mar;47(3):104-8. PubMed PMID: 9562335.

15: McLoughlin M, Kearney AS, Palepu NR. Aqueous stability of SB 210661: kinetics and primary degradation mechanisms of an N-hydroxyurea-containing 5-lipoxygenase inhibitor. J Pharm Pharmacol. 1998 Feb;50(2):127-32. PubMed PMID: 9530978.

16: Li R, Mayer PT, Trivedi JS, Fort JJ. Polymorphism and crystallization behavior of Abbott-79175, a second-generation 5-lipoxygenase inhibitor. J Pharm Sci. 1996 Jul;85(7):773-80. PubMed PMID: 8819005.

17: Howarth PH, Harrison K, Lau L. The influence of 5-lipoxygenase inhibition in allergic rhinitis. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):423-4. PubMed PMID: 7613199.